FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316190195> ?p ?o ?g. }

• W2316190195 abstract "You have accessJournal of UrologySexual Function/Dysfunction: Basic Research & Pathophysiology I1 Apr 2016MP86-16 DOES NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IMPACT ERECTILE FUNCTION RECOVERY POST-RADICAL PROSTATECTOMY? Lawrence C. Jenkins, A. Karim Touijer, Dana Rathkopf, Christian J. Nelson, and John P. Mulhall Lawrence C. JenkinsLawrence C. Jenkins More articles by this author , A. Karim TouijerA. Karim Touijer More articles by this author , Dana RathkopfDana Rathkopf More articles by this author , Christian J. NelsonChristian J. Nelson More articles by this author , and John P. MulhallJohn P. Mulhall More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2324AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) has an evolving role in men undergoing radical prostatectomy (RP) with high-risk prostate cancer. Animal research suggests that ADT leads to structural changes in erectile tissue. We looked to identify the impact of ADT on erectile function recovery (EFR) post-RP. METHODS Study population included men: (i) receiving ADT pre-RP for high-risk disease (ii) who completed baseline and follow-up IIEF questionnaires. Follow-up assessment was ≥18m post RP. Men starting ADT pre-surgery (A) were compared to men who did not receive ADT (N). Patients undergoing salvage RP were excluded. Multivariable analyses (MVA) was used to explore predictors of EFR including were patient age, nerve sparing scores, comorbidity profiles and baseline EFD. RESULTS 1,089 men met the eligibility criteria. 43 in A group, 1,046 in the N group. Mean age = 59±7 years and vascular co-morbidities were 9% diabetes, 41% hypertension, 43% high cholesterol (no difference between groups). Mean time from RP to last post-RP assessment was 3±1.2 years (range =1.5-7 years). No difference in baseline EFD for A vs N groups (25.5±5.1 v 26.2±5.4, p=0.46). At last follow-up, the A group had a significantly lower EFD score than N group (14±7.7 v 19.2±8.6, p<0.001). On MVA, predicting post-RP: baseline EFD, patient age, nerve sparing score, and baseline EFD were all significant predictors (all p values <0.001). ADT was also a significant predictor of post-RP EFD, with A group having a mean EFD score 4.0 points lower than N group (p=0.002). When assessing men with only good baseline EF (EFD≥24), the percentage of men with good EF was similar: A 78% v N 79%, p=0.72. At follow-up, A group had a significantly lower percentage reporting good EF compared to N group: A 19% v N 41%, RR=0.45, 95% CI: 0.23-0.85 p=0.01. Pre-RP, both groups reported a low % of baseline severe ED: A 2%; N 3%, p=0.86. At follow-up, severe ED was more common in A group: A 44% vs. N 24%, RR=1.97, 95% CI: 1.28-2.59, p=0.01. On MVA, in this sub-cohort, ADT was a significant predictor post-RP EFD, A group having a mean EFD score 4.7 points lower than N group (p=0.001). CONCLUSIONS ADT pre-RP leads to worse EFR. While neoadjuvant ADT is currently being explored as strategy for RP patients with high-risk disease, it is important that oncologists appreciate he consequences of this on EFR and should communicate this to patients. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1111-e1112 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Lawrence C. Jenkins More articles by this author A. Karim Touijer More articles by this author Dana Rathkopf More articles by this author Christian J. Nelson More articles by this author John P. Mulhall More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2316190195 created "2016-06-24" @default.
• W2316190195 creator A5002358672 @default.
• W2316190195 creator A5011030409 @default.
• W2316190195 creator A5045658798 @default.
• W2316190195 creator A5072193489 @default.
• W2316190195 creator A5082375766 @default.
• W2316190195 date "2016-04-01" @default.
• W2316190195 modified "2023-10-15" @default.
• W2316190195 title "MP86-16 DOES NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IMPACT ERECTILE FUNCTION RECOVERY POST-RADICAL PROSTATECTOMY?" @default.
• W2316190195 doi "https://doi.org/10.1016/j.juro.2016.02.2324" @default.
• W2316190195 hasPublicationYear "2016" @default.
• W2316190195 type Work @default.
• W2316190195 sameAs 2316190195 @default.
• W2316190195 citedByCount "0" @default.
• W2316190195 crossrefType "journal-article" @default.
• W2316190195 hasAuthorship W2316190195A5002358672 @default.
• W2316190195 hasAuthorship W2316190195A5011030409 @default.
• W2316190195 hasAuthorship W2316190195A5045658798 @default.
• W2316190195 hasAuthorship W2316190195A5072193489 @default.
• W2316190195 hasAuthorship W2316190195A5082375766 @default.
• W2316190195 hasBestOaLocation W23161901951 @default.
• W2316190195 hasConcept C121608353 @default.
• W2316190195 hasConcept C126322002 @default.
• W2316190195 hasConcept C126894567 @default.
• W2316190195 hasConcept C2777899217 @default.
• W2316190195 hasConcept C2779159551 @default.
• W2316190195 hasConcept C2779466945 @default.
• W2316190195 hasConcept C2779929075 @default.
• W2316190195 hasConcept C2780192828 @default.
• W2316190195 hasConcept C2908647359 @default.
• W2316190195 hasConcept C29456083 @default.
• W2316190195 hasConcept C3020768380 @default.
• W2316190195 hasConcept C71924100 @default.
• W2316190195 hasConcept C99454951 @default.
• W2316190195 hasConceptScore W2316190195C121608353 @default.
• W2316190195 hasConceptScore W2316190195C126322002 @default.
• W2316190195 hasConceptScore W2316190195C126894567 @default.
• W2316190195 hasConceptScore W2316190195C2777899217 @default.
• W2316190195 hasConceptScore W2316190195C2779159551 @default.
• W2316190195 hasConceptScore W2316190195C2779466945 @default.
• W2316190195 hasConceptScore W2316190195C2779929075 @default.
• W2316190195 hasConceptScore W2316190195C2780192828 @default.
• W2316190195 hasConceptScore W2316190195C2908647359 @default.
• W2316190195 hasConceptScore W2316190195C29456083 @default.
• W2316190195 hasConceptScore W2316190195C3020768380 @default.
• W2316190195 hasConceptScore W2316190195C71924100 @default.
• W2316190195 hasConceptScore W2316190195C99454951 @default.
• W2316190195 hasIssue "4S" @default.
• W2316190195 hasLocation W23161901951 @default.
• W2316190195 hasOpenAccess W2316190195 @default.
• W2316190195 hasPrimaryLocation W23161901951 @default.
• W2316190195 hasRelatedWork W1981635576 @default.
• W2316190195 hasRelatedWork W1992929525 @default.
• W2316190195 hasRelatedWork W2044284566 @default.
• W2316190195 hasRelatedWork W2061894886 @default.
• W2316190195 hasRelatedWork W2314391848 @default.
• W2316190195 hasRelatedWork W2402249956 @default.
• W2316190195 hasRelatedWork W2530461552 @default.
• W2316190195 hasRelatedWork W2895337261 @default.
• W2316190195 hasRelatedWork W2929757083 @default.
• W2316190195 hasRelatedWork W4319748405 @default.
• W2316190195 hasVolume "195" @default.
• W2316190195 isParatext "false" @default.
• W2316190195 isRetracted "false" @default.
• W2316190195 magId "2316190195" @default.
• W2316190195 workType "article" @default.